NASDAQ:MIRA MIRA Pharmaceuticals Q2 2026 Earnings Report $0.86 +0.02 (+2.44%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast MIRA Pharmaceuticals EPS ResultsActual EPS-$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMIRA Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMIRA Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsMIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile MIRA Pharmaceuticals Earnings HeadlinesMIRA Pharmaceuticals (NASDAQ:MIRA) Coverage Initiated at Maxim GroupSeptember 19, 2026 | americanbankingnews.comMaxim Initiates MIRA Pharmaceuticals at Buy With $3.50 Price TargetSeptember 18, 2026 | marketscreener.comMBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 25 at 1:00 AM | Decentralized Masters (Ad)MIRA Advances Phase 2a Study Of Ketamir-2 For Chemotherapy-Linked Neuropathy; Stock UpSeptember 17, 2026 | rttnews.comMIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA ReviewSeptember 17, 2026 | globenewswire.comMIRA-55 toxicology results advance non-opioid pain programSeptember 1, 2026 | tipranks.comSee More MIRA Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email. Email Address About MIRA PharmaceuticalsMIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on developing novel treatments for neurological and neuropsychiatric disorders. The company’s research is directed toward therapies for conditions with significant unmet medical needs, including anxiety, depression and chronic pain. MIRA’s lead product candidate, MIRA-55, is an oral ketamine analog being developed for potential use in anxiety, depression and neuropathic pain. The company is evaluating the compound’s therapeutic potential and safety as it advances its development program. MIRA Pharmaceuticals is headquartered in the United States and is led by Chief Executive Officer Erez Aminov. As an early-stage drug developer, the company’s operations are primarily focused on pharmaceutical research, clinical development and pursuing regulatory pathways for its pipeline candidates.View MIRA Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
